All In Biotech

Drug Trial Radar · NCT07178002

OM 85 to Prevent Respiratory Infections in Older At Risk Patients

Last checked: Nov 19, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Dec 19, 2024

Primary completion

Jan 2026

Study completion Apr 2026

Sponsor

Lead sponsor
Fondazione Policlinico Universitario Campus Bio-MedicoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
OM Pharma SA
First posted
Sep 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 7 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

People living in NH are at higher risk of respiratory infections compared to their counterpart living in the community. Products obtained from dead bacteria ("bacterial lysate") can be used to boost immune system and may reduce the risk of respiratory infections. Very little information is available on the effect of these substances in older people. This study will evaluate the efficacy of a bacterial lysate in reducing the incidence of lower respiratory tract infections in older people living in nursing homes. The study will include a treatment arm, in which participants will received the lysate, and a control arm in which participants will received a matching placebo (i.e., a pill that has the same appearance of the lysate but does not contain the lysate itself).

Conditions

  • Respiratory Tract Infections (RTI)

Interventions

  • Bacterial LysateDrug

    Administration p.o. for 10 days per month for 3 months, two consecutive cycles.

  • PlaceboDrug

    Matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of lower respiratory tract infections.Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fondazione Policlinico Universitario Campus Bio Medico

    Roma, Italia, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.